No Data
No Data
Express News | Affimed Demonstrates Increased AFM24 Exposure Correlates With Improved Response Rates And Progression-Free Survival In Refractory NSCLC Patients At AACR Annual Meeting
Affimed Says Abstract On Phase 2 LuminICE-203 Study Of ICE Acimtamig In Combination With AB-101 Accepted For Oral Presentation At ASCO 2025
Affimed Receives Nasdaq Notice Over Low Share Price, Has Until October to Regain Compliance
Leerink Partners Maintains Affimed NV(AFMD.US) With Buy Rating, Cuts Target Price to $5
H.C. Wainwright Maintains Affimed NV(AFMD.US) With Buy Rating, Maintains Target Price $7
Truist Financial Maintains Affimed NV(AFMD.US) With Buy Rating